TP53 and lymphoma: Moreover, the inhibition of SFKs with the small molecule dasatinib [10, 11] in combination with the compound PRIMA, which reactivates mutant p53 [12-14], leads to an increase of the endogenous p53-SOCS1 interaction in human lymphoma SU-DHL4 cells [4].